The problem, Zaaijer explained, is that algorithms used in precision medicine models overwhelming are built on DNA with ...
Ivo Carre, PhD, shares subgroup data that points to potential benefit in younger patients with high-risk MDS.
Epcoritamab addition to R2 significantly improves progression-free survival and overall response rates in relapsed follicular ...
Fixed-duration venetoclax regimens showed non-inferior progression-free survival compared to continuous ibrutinib in CLL ...
Continuous variable modeling such as the Hodgkin lymphoma international prognostic index (A-HIPI) improves prognostic ...
A recent clinical trial found that a new TROP2-targeted antibody-drug conjugate (ADC) showed encouraging efficacy in treating ...
Families with children treated for ALL often face catastrophic financial toxicity, including severe income loss and inability to afford basic needs. Financial strain typically intensifies six months ...
Innovations such as nurse navigators, AI-assisted prior authorizations, and community education—including rural outreach—are ...
The decision to use newer agents in relapsed/refractory follicular lymphoma is heavily influenced by the disease’s inherent ...
The upcoming American Society of Hematology (ASH) 2025 meeting is poised to spotlight several pivotal developments across ...
Antonio Urbina, MD, the medical director for the Mount Sinai Institute for Advanced Medicine 7th Avenue clinic in New York ...
Panelists discuss how PCSK9 inhibitors remain underused due to access, cost, and adherence barriers.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results